 |
 |
 |
Journal articles
Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network
https://hal-univ-rennes1.archives-ouvertes.fr/hal-02182035
Contributor : Accord Elsevier CCSD Connect in order to contact the contributor
Submitted on : Monday, October 25, 2021 - 1:51:39 PM
Last modification on : Friday, August 5, 2022 - 3:37:03 AM
Long-term archiving on: : Wednesday, January 26, 2022 - 8:21:18 PM
Contributor : Accord Elsevier CCSD Connect in order to contact the contributor
Submitted on : Monday, October 25, 2021 - 1:51:39 PM
Last modification on : Friday, August 5, 2022 - 3:37:03 AM
Long-term archiving on: : Wednesday, January 26, 2022 - 8:21:18 PM
File
S0959804919303508.pdf
Files produced by the author(s)
Licence
Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License